Mark Gudesblatt
3PUBLICATIONS
15CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Feb 18, 2026
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.Ahmed Z Obeidat, Michelle Betz, Rebecca Straus Farber
|Jun 27, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.Barry A Singer, Sibyl Wray, Mark Gudesblatt
|Jun 11, 2024
De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.Mark Gudesblatt, Barbara Bumstead, Marijean Buhse
Pageof 1
Frequent Collaborators
2 joint publications
Jason P Mendoza
2 joint publications
James B Lewin
2 joint publications
Sai L Shankar
1 joint publications
Barry A Singer
1 joint publications
Tjalf Ziemssen
1 joint publications
Matthew Scaramozza
1 joint publications
Ahmed Z Obeidat
1 joint publications
Erica Goff
1 joint publications
Le H Hua
1 joint publications
Yang Mao-Draayer
